Keyword: Samsung

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.

AbbVie shielded Humira from another U.S. biosims threat in a deal that makes it "increasingly unlikely" any copycats will launch here before 2023.

New research takes a wide look at the strategy of "evergreening," or adding new patents to extend a drug's exclusivity.

Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.

Johnson & Johnson has successfully fended off most Remicade biosimilar competition, and it has a three-pronged strategy to thank.

J&J's Remicade is holding its own against a U.S. biosimilar rival—so much so, the company says, that it’s not worried about a second entrant.

Dead set on defending its top drug, Johnson & Johnson is taking South Korea’s Samsung Bioepis to federal court over a biosim launch.

WuXi AppTec started IPO prep for core drug R&D, Purdue and Shionogi won approval for a new constipation med, and an Indian CRO's meds were halted by EMA.

Biogen rolled out its Remicade biosimilar in the U.K., thus becoming the first drugmaker to market two anti-TNF biosims there. But don't expect anyone to pull off a similar feat in the U.S. anytime soon.